UNSPSC 51362702: Mefeclorazine

This classification denotes a sedative and hypnotic with the molecular formula C20H25ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IM840F32VV, chemically known as 1-o-chlorophenyl-4-(3,4-dimethoxyphenethyl)piperazine but generally known as mefeclorazine, which bears US NIH Compound Identifier 71066. European Medicines Agency schedules Mefeclorazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08702MIG.

UNSPSC 51362702 Mefeclorazine is a Commodity code that does not reflect the actual pharmaceutical procurement activity currently posted under it by state and local buyers. The recent opportunities tagged to this code involve naloxone distribution, generic multi-source pharmaceuticals, and therapeutic pharmacy initiatives—none of which are mefeclorazine specifically. The code appears to be a mismatch with the work being solicited, and the source provides no evidence of state or local governments actively procuring mefeclorazine itself.

Recent activity under this code comes from Seminole County, Florida (naloxone and drug deactivation systems procurement via IFB), the Texas Health and Human Services Commission (exploratory RFI on direct-to-manufacturer prescription programs), and the Minnesota Multistate Cooperative Purchasing Alliance (generic pharmaceuticals and OTC products across multiple states and local governments). The geographic spread includes Florida, Texas, and Minnesota, with MMCAP's cooperative vehicle serving broader multistate participation including Oregon. The Seminole County IFB (Solicitation IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Minnesota MMCAP RFP (Solicitation S1070000015802, due March 26, 2026) established contracts for generic multi-source pharmaceuticals and OTC products across state and local facilities with pricing evaluations weighted 75 percent on competitiveness; and the Texas HHS RFI (Solicitation HHS0017013, posted April 3, 2026) gathered market intelligence on direct-to-manufacturer prescription programs. This code shows little relevant recent activity aligned with its nominal scope.